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Abstract 
Adequate quality is essential for any medicinal product to be eligible for marketing. Quality includes 
verification of the identity, content and purity of a medicinal product in combination with a specified 
production process and its control. Allergen products derived from natural sources require particular 
considerations to ensure adequate quality. Here, we describe key aspects of the documentation on 
manufacturing and quality aspects for allergen immunotherapy products in the European Union and 
the United States. In some key parts, requirements in these areas are harmonized while other fields 
are regulated separately between both regions. Essential differences are found in the use of 
Reference Preparations, or the requirement to apply standardized assays for potency determination. 
Since the types of products available are different in specific regions, regulatory guidance for such 
products may also be available in one specific region only, such as for allergoids in the European 
Union. Region-specific issues and priorities are a result of this. As allergen products derived from 
natural sources are inherently variable in their qualitative and quantitative composition, these 
products present special challenges to balance the variability and ensuring batch-to-batch 
consistency. Advancements in scientific knowledge on specific allergens and their role in allergic 
disease will consequentially find representation in future regulatory guidelines.  
 
Introduction 
Allergens used in the diagnosis and treatment (Allergen immunotherapy (AIT)) of type I allergies are 
biological medicinal products. An essential prerequisite for any detailed consideration of a specific 
allergen product with regard to safety and efficacy is that these are of sufficient quality, i.e. with 
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respect to identity, content and purity. For biological products, such quality is highly dependent on 
the manufacturing process and the capability of this process to produce a consistent product and 
control its quality accordingly. For the European Union (EU), Directive 2001/83/EC defines a 
biological substance as a substance that is produced by or extracted from a biological source and 
that needs for its characterization and the determination of its quality a combination of physico-
chemical-biological testing, together with the production process and its control (1). In line with this, 
the manufacturing process is considered to be one of the defining characteristics for a product. 
Consequently, two products produced from the same source material but using differing 
manufacturing processes should be considered to be different products, unless their comparability 
with regard to their qualitative and quantitative composition has actually been demonstrated. Even 
potentially small differences in the manufacturing, e.g. of the extraction process (2–4), may result in 
considerable differences between  products. Sufficient quality of allergen products and consistency 
of batches are considered to be prerequisites for successful application of these products in clinical 
practice (5–7). Only when consistency of quality within clinical batches and in comparison to batches 
to be marketed is assured, can efficacy and safety (to be proven by respective clinical 
documentation) be expected to be similar. To comply with these requirements, numerous 
regulations need to be considered and followed by allergen manufacturers. The main aspects 
addressed in these guidance documents are appropriate control of the manufacturing process, the 
intermediates and products produced, and appropriate batch-control testing (8). Based on the range 
of clinical trials performed (9, 10), Europe and the United States (U.S.) may arguably be the most 
important regions for the gathering of clinical evidence and the subsequent marketing authorisation 
application of candidate AIT products. Here, we provide an overview of how AIT products are 
regulated with respect to their manufacturing and quality aspects in Europe and the U.S. As in both 
regions there are currently only AIT products available that are derived from natural extracts, we 
focus on this type of product.   While an overview on the regulation of AIT products in different parts 
of the world (11) as well as some key aspects concerning the regulation and standardization of AIT 
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extracts in the EU and U.S. (12) have been previously published, an actual comparison of 
manufacturing and quality aspects between Europe and the US has not been described and 
discussed so far for allergen products.  
In recent decades, multiple areas have experienced harmonization between the U.S. and the EU. For 
instance, marketing authorization applications are compiled according to a shared format - the 
Common Technical Document (CTD). An overview on the most important segments with respect to 
the quality documentation is summarized in Table 1. The respective requirements on the content of 
these dossiers are mostly harmonized within Europe and guidance developed by the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) are applied widely, including in Europe, the US and Japan. ICH guidelines already 
cover a wide range of issues, amongst others stability issues, changes in the manufacturing process, 
validation of manufacturing processes and test methods, and quality systems (for example (13–20)). 
Current Good Manufacturing Practice (cGMP) regulations apply to the manufacturing of drug 
products and biologic products in both the EU and the U.S., assuring the identity, strength, quality, 
and purity of drug products by requiring that manufacturers adequately control manufacturing 
operations. This includes establishing strong quality control management systems, obtaining 
appropriate quality raw materials, establishing robust operating procedures, detecting and 
investigating product quality deviations, and maintaining reliable testing laboratories (21). However, 
when it comes to the requirements for the quality documentation of an allergen product to be 
provided by allergen manufacturers to obtain marketing authorization, there are also diverging 
approaches between the EU and the U.S.   
This analysis has been prepared by the European Academy of Allergy and Clinical Immunology’s 
(EAACI) Taskforce on Regulatory Aspects of Allergen Immunotherapy (AIT) and is part of the EAACI 
AIT Guidelines. Pertaining to these guidelines, we have previously described the general regulatory 
approaches for AIT products in selected parts of the world (11).  
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Legal requirements and guidance on manufacturing and quality aspects in Europe 
In Europe, Article 8(3) in accordance with Annex I of the Directive 2001/83/EC represents the basis 
for the request for quality documentation to be provided for marketing authorization of a medicinal 
product. As also referenced here, the European Pharmacopoeia (Ph. Eur.), which is a collection of 
pharmaceutical rules developed by the European Directorate for the Quality of Medicines & 
Healthcare (EDQM), are applicable and thus mandatory to be followed by manufacturers. The Ph. 
Eur. includes monographs on specific medicinal products (such as the monograph on allergen 
products (22) or the monograph on parenteralia (23)) as well as on pharmaceutical test methods. 
The monograph on allergen products applies to allergen products manufactured from natural 
sources, thereby excluding allergens derived by recombinant DNA technology and epicutaneous test 
allergens of chemical origin such as fragrances. It describes acceptance criteria for the source 
materials, manufacturing requirements and testing of the final product. It states requirements for 
the purity, identity and potency of allergen products, but also includes specific requests for subtypes 
of allergen products, for example, mandatory potency testing of therapeutic allergens and the 
requirement of sterility testing for skin prick tests. In addition, the monograph also defines standards 
for the establishment of an In-house-reference-preparation (IHRP). In the 1980’s, several 
international collaborative studies developed reference preparations for allergens that have become 
acknowledged by the World Health Organization (WHO) as International Standards for Allergens. 
However, these standards inherited a number of shortcomings, for example incomplete information 
on their preparation and dependence on individual protocols resulting in lack of comparableness of 
assigned units (24). They are therefore rarely used in practice. As a result, and as long as no 
internationally harmonized and agreed standards are available allowing comparison of products 
from different manufacturers, each manufacturer establishes its own IHRP for each respective 
product, consequentially resulting in labelling of arbitrary in-house units. This IHRP is then used as a 
standard to compare batches produced for the market (e.g. for identity verification or potency 
testing). As a result of this modus operandi, there are substantial differences in the individual 
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allergen contents of the marketed products (25–28). Due to the different and non-standardized 
assays applied, these characteristics are not directly comparable and critically these differences are 
not evident to the physician or the patient. Although there are only few data available on the effect 
of differing contents of major allergen on clinical efficacy (29–31), better comparability of these 
products would be highly desirable (5, 32). The currently ongoing BSP090 project of the EDQM aims 
at developing standards for the quantification of certain allergens and has already developed 
European Pharmacopeia reference standards for the major grass allergen Phl p 5 and the major birch 
allergen Bet v 1 (33, 34) as well as validated methods for the quantification of Bet v 1 (35). In 
addition to the aforementioned monograph on allergen products, recently, several monographs on 
allergen source materials have been included in the Ph. Eur., each covering a separate group of 
allergens (36–40). It should be noted that, although defining a common set of standards for the 
source materials, these monographs allow much flexibility in the choice of methods used for 
characterization. It therefore remains within the responsibility of the manufacturers to choose and 
justify those methods most suited to reliably characterize respective source materials.  
Furthermore, guidelines developed by different parties, such as working groups of the European 
Medicines Agency (EMA), the WHO and ICH, form an extensive collection of documents giving 
guidance on various aspects of the manufacturing of medicinal products, including allergen 
products. Concerning the quality and manufacturing issues of allergen products, the “Guideline on 
Allergen Products: Production and Quality Issues” (41)  developed by EMA’s Committee for 
Medicinal Products for Human Use (CHMP) and the associated Biologics Working Party (BWP) is the 
most important allergen specific guidance available. Drafted in 2008, it gives the most up-to-date 
overview of the requirements to be considered for allergen manufacturing and controls thereof. In 
contrast to the aforementioned monograph on allergen products, it covers the manufacturing of 
allergens from both natural as well as biotechnological sources. The guideline details aspects of 
manufacturing and process controls for various stages of the manufacturing process, including 
specific considerations on the source materials, the drug substance and the drug product. One 
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crucial aspect presented in this guideline is the concept of homologous groups. According to this 
concept, allergens from related species can be integrated in a homologous group (42). Overall, the 
guideline proposes six different homologous groups (for trees (Fagales group, Oleaceae group, 
Cupressaceae group), grass and cereal pollen, weeds, and mites). These groups may be extended 
and new groups may be formed if certain criteria are fulfilled (Table 2). Within a homologous group, 
extrapolation of data on clinical efficacy and safety as well as limited data on quality aspects (such as 
process validation and stability studies) from a representative species to other species of the same 
group are accepted by regulatory bodies. 
In addition, the guideline specifies requirements for different types of allergen products produced, 
e.g. considerations on the demonstration of stability as well as laying out a framework for 
characterization of allergoids.  
 
Characterization of allergoids in the EU 
Allergoids are allergens that are chemically modified (e.g. by treatment with glutaraldehyde or 
carbamylation) to reduce IgE activity (43) and are commonly available on the European market. 
Many of these are additionally adsorbed to carriers such as Aluminium hydroxide. The 
characterization of this group of products is especially challenging as, due to the resulting cross-
linking, various critical tests cannot be performed after the chemical modification. Therefore, 
specific tests such as determination of total allergenic activity are not performed at the drug product 
stage but earlier in the manufacturing process, e.g. at the stage of the native allergen extract. As a 
result, the manufacturer must take additional measures (e.g. by setting appropriate in-process 
limits) to ensure that the potency of the final drug product still remains within a controlled range 
even though it cannot be further determined after  modification.  For certain modifications, the 
identity of the drug product cannot be confirmed by common test methods (e.g. protein profile by 
SDS-PAGE) that are typically applied to native extracts. Nevertheless, manufacturers must monitor 
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several quality attributes of these products, including the efficacy and stability of the adsorption, for 
example by determining the total soluble protein and/or the presence of IgE-binding components in 
the supernatant. With the latest version of the EMA Guideline on the quality of allergen products 
(41), additional requirements were introduced to allow further in-depth characterization. Test 
methods have to be established to identify the relevant allergens in the modified form. 
Furthermore, potency tests are required that allow discrimination between native and modified 
molecules. These tests should permit a quantitative conclusion on the content of the active 
substance after modification and should be specific to confirm the identity of the modified drug 
substance. An in-depth review on qualitative aspects concerning allergoids can be found in a recent 
review by Zimmer et al (44). 
 
Legal requirements and guidance on manufacturing and quality aspects in the U.S. 
In the US, the basis for manufacturing and quality requirements for allergen products are U.S. laws 
(Acts) and Federal Regulations. Allergen products are regulated by the U.S. Food and Drug 
Administration (FDA) as biologic products (biological medicinal products) under the Public Health 
Service Act (PHS Act) and related amendments; and as drug products under the Federal Food, Drug 
and Cosmetics Act (FD&C Act) and related amendments. Additional laws may contain important 
provisions for regulation of biological products and drug products, but the PHS Act and FD&C Act 
and their related amendments are the primary laws under which biological products are regulated. 
The US Congress has the sole authority to enact federal laws in the US. Laws authorize or require 
that federal agencies develop regulations through a public rulemaking process that include details 
necessary for implementation. Federal Regulations, which have the force of law, specify 
manufacturing and quality requirements for drug products, biologic products, medical devices, and 
foods. Federal regulations for FDA-regulated products are located in Title 21 of the Code of Federal 
Regulations (21 CFR). U.S. laws and regulations provide the critical legal framework for regulation of 
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allergen products, and are designed to ensure that allergen products meet manufacturing and 
quality standards and are safe, pure, and potent. Additionally, the FDA has developed guidance 
documents that describe FDA’s current thinking on a range of regulatory topics including 
manufacturing and product quality. FDA guidance documents are not legally binding on FDA or the 
public and allow for use of alternative approaches provided they satisfy the requirements of the 
applicable laws and regulations. Finally, as stated above, several ICH guidance documents are also 
applicable to allergen products and provide a harmonized approach on certain manufacturing and 
quality related issues.   
With some exceptions, manufacturing and quality requirements for allergen products are similar to 
those for other biologic products or drugs.  Generally, manufacturing and quality standards do not 
differ between allergen products approved for diagnosis or therapy.   FDA‘s main regulatory 
standard for ensuring product quality is the cGMP regulations for finished pharmaceuticals, located 
at 21 CFR parts 210 and 211.   The regulations contain the minimum cGMP standards for methods to 
be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or 
holding of a drug.  Application of cGMPs are intended to assure that a drug meets the requirements 
of the FD&C Act as to safety, and the drug has the identity and strength and meets the quality and 
purity characteristics that it purports or is represented to possess.  Additional cGMP requirements 
for biologics are located at 21 CFR parts 600-680, and specific requirements for allergenic products 
are located at 21 CFR part 680.  Although the cGMP regulations at 21 CFR parts 210 and 211 
specifically refer to finished pharmaceuticals; compliance with general principles of cGMPs is also 
required under the FD&C Act. FDA guidance documents inform applicants on approaches to 
complying with cGMPs.  Examples of guidance document topics include process validation principles 
and practices (45), sterile drug products produced by aseptic processing (46) analytical procedures 
and methods validation for drugs and biologics (47), and quality systems approach to cGMP 
regulations (48). Harmonization has been achieved in several areas relevant to cGMP and quality 
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systems that are applicable to allergen products, including ICH guidance documents for stability 
studies (14), methods validation (16), and quality systems (17–20). 
As indicated above, cGMP requirements for allergen source materials and allergen products are 
located at 21 CFR part 680. Allergen source material regulations include testing and quality 
requirements for pollen, mold, mammalian and avian source materials (21 CFR 680.1).  Basic 
requirements for allergen product manufacturing include limits on extraneous allergenic substances 
during the manufacturing process and in culture media used in production (21 CFR 680.1).  Specific 
testing requirements include identity and potency (21 CFR 680.3).  The potency test regulation (21 
CFR 680.3(e)) is specifically related to sterile injectable allergen extracts derived from natural 
biologic source materials that are currently licensed for diagnosis and treatment of Type I allergies.  
Currently licensed allergen extracts are identified as standardized or non-standardized.  The potency 
test regulation requires that the potency of each lot of allergenic extract be determined according to 
a potency test method that measures the allergenic activity of the product.  Historically, in addition 
to development of a suitable potency test, FDA develops and maintains U.S. reference standards and 
serum pools used by licensed manufacturers for final drug product release testing of each lot of 
standardized extract and for routine stability studies. Standardization ensures that standardized 
allergen extracts have a consistent measure of potency across manufacturers. The potency test 
regulation further specifies that licensed manufacturers may continue to use non-standardized units 
until notified by FDA of the existence of a potency test. Accordingly, non-standardized extracts are 
labeled in units of weight/volume (w/v) or protein nitrogen units (PNUs), and are exempt from 
stability testing [ 21 CFR 211.166(d)] and identity testing [21 CFR 680.3(a)].  The approach to 
standardization and designation of allergenic extracts as standardized or non-standardized allergenic 
extracts is applicable to currently licensed extracts.  This approach may not apply to future extracts 
or new types of products such as peptides or recombinant products.  FDA assesses each product 
during the development and licensure phase to determine the applicable potency unitage.   
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Additional regulations under the General Biological Products Standards (21 CFR Part 610) also apply 
to allergenic extracts. These regulations include requirements for lot release, sterility testing, 
constituent materials (ingredients and preservative content) and cultures used in manufacturing. In 
addition to specific regulatory requirements, FDA’s Guidance for Submission of Chemistry, 
Manufacturing, and Controls Information for Allergenic Products (49) details additional 
considerations for source materials and manufacturing and process controls for the drug substance 
and the drug product.   
 
Differences in Regulatory Approaches Between the EU and the U.S.  
The EMA Guideline on Allergen Products: Production and Quality Issues (41)  delineates specific 
approaches to use of IHRPs and homologous groups that are different from U.S. approaches.  For 
U.S. standardized allergen extracts, a national reference standardized to maintain consistent 
potency among U.S. manufacturers.  FDA permits the use of IHRPs properly calibrated to U.S. 
reference standards for standardized extracts although this approach is rarely used. For non-
standardized extracts, IHRPs are not used because:   
1. As non-standardized extracts are explicitly exempted by regulation from potency testing 
and stability studies, there is no inherently obvious role for use of IHRPs, and    
2. The proprietary biological unitage associated with IHRP use would raise significant 
concerns in the U.S. about potentially increasing the variability that already exists among 
non-standardized extracts.   
 
With respect to homologous groups, the EMA guideline formalizes an approach to homologous 
groups of allergen species, based on manufacturing similarities and cross-reactivity among allergen 
species from a taxonomic group. Proposed groups (see above) are based on existing data, although 
manufacturers may propose additional groupings from new data. According to EMA guidance (41, 
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50), data may be extrapolated from one member of a homologous group to others in support of 
product quality and even clinical claims. Although FDA guidance documents have not delineated 
similar regulatory treatment of allergen extracts with either cross-reactive or otherwise similar 
source materials, the FDA has applied comparable logic in its analyses of non-standardized allergen 
extracts (51), and in a recent Biologics License Application (BLA) approval for a sublingual tablet 
formulation for which the data supported a broader indication for the product.  
The EMA guideline also provides specific requirements for distinct types of allergen products such as 
recombinant allergens or synthetic peptides, or novel classes of active substances such as allergoids 
or conjugates. These types of allergen products are not currently licensed in the U.S. Regardless of 
allergen product type, FDA reviewers work with Investigational New Drug (IND) Sponsors and BLA 
Applicants to establish the safety and efficacy of the product, and to ensure that the manufacturing 
process is properly designed and validated; quality is built into the process; test methods are 
suitable for their intended use and provide adequate control of the manufacturing process and the 
product; conformance to cGMPs is established; and consistency with clinical lots is demonstrated.   
 In the U.S., allergen products in transdermal patch delivery systems and pre-filled syringes are 
considered combination products under the FD&C Act and the regulations at 21 CFR Part 3  (52).  
Applicants seeking licensure for such products must meet applicable regulatory requirements for 
combination products during the clinical development and licensing phases as well as the post-
approval phase. Certain FDA guidance documents for combination products and transdermal drug 
delivery systems may apply to allergen products (53, 54).  An overview on key similarities and 
differences in the regulation of allergen manufacturing and quality control between the EU and the 
U.S. is depicted in table 3. 
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Variability in the product characteristics of AIT products 
Production and control of allergen products derived from natural extracts can prove to be a 
considerable challenge. The complexity of the source material and the final product is high, as it is 
composed not only of a mixture of allergenic proteins, but also of non-allergenic proteins as well as 
other non-allergenic compounds. There is high variability in the source material itself resulting in 
final products that mirror this variability. This is also reflected by the comparably wide acceptance 
criteria allowed by the European Pharmacopoeia for the testing of allergen products (22).  
For example, the potency as determined by the total allergenic activity may vary between 50 to 150 
% of a stated amount (22). This wider limit is required given the variability between batches of 
starting material but also to accommodate for the inherent variability of the (mostly 
immunochemical) potency assays. Accordingly, a batch produced at a total allergenic activity of 50% 
would be in line with a given specification and, presuming that all other specifications are fulfilled as 
well, could be marketed. The same would be true for a batch at the higher end of the specification 
(e.g. at 150% of a stated amount). In consequence, substantial variation with regard to the potency 
of an allergen product is possible where a new batch is being applied to a patient. However, it should 
be noted that a product must comply with such specifications over its whole shelf life, which implies 
that given some expected decrease over time the levels at release should not be at the lowest 
specification level. Similar to the determination of total allergenic activity, such circumstances are 
observed for additional parameters such as the determination of the total protein content (for 
therapy allergens, a range of 50 to 150% is allowed) and the determination of individual allergens, 
where a range of 50 to 200 % is allowed. Figure 1 illustrates the variation that would be possible for 
a hypothetical product in regard to the content of individual allergens. However, applicants must 
justify a chosen specification and it may be required to tighten such specification beyond the limits 
requested by the Ph. Eur (22). Monographs are considered to demand minimum requirements. 
Furthermore, there are also specific in process controls (IPCs; e.g. protein content and allergenic 
activity) that are typically applied and monitored during manufacturing. Trend analysis of such IPCs 
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in the manufacturing process is applied to prevent that the variability in the starting material leads 
to extensive batch-to-batch variation in potency. It therefore is a balancing act of allowing some 
variation to account for this while restricting variation to an acceptable degree to secure batch-to-
batch consistency.  
Even with such comparably wide ranges allowed, the natural origin of the source materials of AIT 
products can result in considerable difficulties. As it is essential that a medicinal product can be 
produced consistently and its qualitative and quantitative composition remains comparable and 
consistent throughout its lifecycle, a manufacturer must ensure that the manufacturing process is 
flexible enough to balance variances and trends in the composition of the source material, and that 
such trends are recognized as early as possible. For example, it has been reported that the allergenic 
composition of pollen is changing as a long-term trend, possibly due to climate change (55). As it is 
not possible to simply change the strength or composition of a product due to such observations, 
e.g. with respect to the overall allergenic activity, the process must assure that the product can still 
be produced according to the given quality characteristics and in assurance of batch-to-batch 
consistency.  
 
Future perspectives  
Despite much progress achieved in harmonization, there remain considerable differences in the in-
depth quality and manufacturing requirements between the U.S. and the EU. Regional specific issues 
and priorities are a result of this. There appears to be consensus in Europe that updating of existing 
regulations may be needed here to account for the changes in the landscape of available allergen 
products observed in this region. Scientific guidance and legislation may need to differentiate more 
between certain types of allergen products. For example, in the EU, current guidance applicable to 
allergen products only scarcely considers the impact of allergy prevalence. In the Guideline on 
Allergen Products: Production and Quality Issues  (41) some initial considerations are presented for 
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products where certain tests may not be applicable (e.g. “because a sufficient number of patients is 
not available to create an appropriate sera pool”). Staggered requirements for quality and/or clinical 
data in dependence of the prevalence of a specific allergy may be a path forward to support the 
market availability of a wider array of products while, at the same time, securing the quality, efficacy 
and safety of these products as far as possible. 
Finally, a comprehensive characterization of AIT products with regard to quality aspects remains 
essential. While current guidelines already implemented the request on the definition and 
verification of the presence of relevant allergens for each product (22, 41), the knowledge on which 
the relevant allergens for specific types of allergies are is rapidly increasing, as has been shown for 
Bet v 1 in birch pollen allergic patients (56, 57). Another example concerns hymenoptera AIT where 
it has been suggested that minor allergens are critically important in the probability of success of the 
treatment for some patients (58). Accordingly, choosing products that reliably contain such critical 
compounds for specific patients may become essential. As analytical procedures evolve and allow 
more precise characterizations of allergen products, it is safe to predict that the regulatory 
framework will follow these developments with some follow-up time. In line with this and 
considering that allergens are the defining elements for the efficacy of these products, demands on 
their characterization and verification with regard to identity and quantity on a routine basis in these 
products will likely intensify in the future. 
 
Disclaimer 
The views expressed in this review are the personal views of the authors and may not be understood 
or quoted as being made on behalf of or reflecting the position of the respective national competent 
authorities, the European Medicines Agency or one of its committees or working parties. 
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Table 1: Simplified overview on critical segments of a marketing authorisation dossier with respect 
to the documentation on the quality of a medicinal product 
 
 
 
 
 
 
 
 
Data on the manufacturing of the active 
substance 
Data on the manufacturing of the finished product
General Information on the active substance Description and composition of the medicinal product
Description of Pharmaceutical Development 
typically addressed in finished product section 
Pharmaceutical development 
• Components of the Medicinal Product 
• Manufacturing Process Development 
• Microbiological Attributes 
Manufacturing process of the active substance
• Manufacturing process description 
• Control of Materials 
• Control of Critical Steps and 
Intermediates 
• Process Validation 
• Manufacturing Process Development 
Manufacturing process of the finished product 
• Batch Formula 
• Manufacturing process description 
• Control of Critical Steps and Intermediates 
• Process Validation 
Control of excipients typically not applicable for 
the active substance 
Control of Excipients
Control of the active substance 
• Specifications 
• Description of analytical procedures 
• Validation of analytical procedures 
• Batch Analysis Data 
• Justification of Specification 
Control of the finished product 
• Specifications 
• Description of analytical procedures 
• Validation of analytical procedures 
• Batch Analysis Data 
• Characterization of Impurities 
• Justification of Specification 
Reference standards or materials Reference standards or materials 
Stability of the active substance Stability of the finished product 
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Table 2: The concept of homologous groups as stated in (41) 
Criteria for grouping as homologous 
groups 
Data extrapolation 
allowed  
Homologous groups as accepted in (41)
Comparable physicochemical and 
biological properties of the source 
material 
Stability data Birch group (Alder, Hornbeam, Hazel, 
Oak, Sweet Chestnut, Beech)  
Cross-reactivity/Structural homology of 
the allergens 
Manufacturing 
process validation 
Oleaceae group (Olive, Ash, Privet, Lilac)
Identical formulation of the finished 
product 
Efficacy Cupressaceae group (Cedar, Cypress)
Identical production process of the 
allergen extract and of the finished 
product 
Safety Sweet grasses (Sweet vernal grass, Oat, 
Cocksfoot, Meadow fescue, Velvet grass, 
Barley, Perennial ryegrass, Timothy grass, 
Kentucky bluegrass, Cultivated rye, 
Cultivated wheat) 
 Weed pollen (Ragweed, Mugwort, 
Pellitory) 
 House dust mites (Dermatophagoides 
pteronyssinus, Dermatophagoides 
farinae) 
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Figure 1: Choosing the house dust mite allergens Der f 1 and Der f 2 as examples, displayed is the 
theoretical range allowed by the European Pharmacopeia for the content of individual allergens (50 
to 200 % of the stated amount of each relevant allergen component). Any value between 0.5 and 2 
would be accepted for a batch to be produced the individual allergens, respectively. 
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 Table 3: Key similarities and differences in the regulation of allergen manufacturing and quality 
control  between the EU and the U.S.. Approaches may differ to some extent for different types of 
products (e.g. subcutaneous vs sublingual products). 
 
 
 
Key similarities Key differences 
 
• Harmonized use of ICH-Guidelines in 
various areas, including stability studies, 
methods validation, quality systems 
 
• Applicability of cGMP regulations 
 
• Common Technical Document format for 
regulatory procedures 
 
• EU: Extrapolation of quality, non-clinical 
and clinical data based on homologous 
groups possible according to [Ref] 
US: Concept of homologous groups not 
delineated in FDA guidance, but 
comparable concepts can be applied 
 
• Consistency of the manufacturing 
process and of batches used for clinical 
development must be demonstrated 
• Regulation is also based on region 
specific laws, regulations, and guidelines 
 
• EU: Allergen products are regulated by 
the National Competent Authorities of 
the EU member states, EMA and its 
committees 
US: Regulated by the FDA 
 
• EU: Use of manufacturer-specific in-
house reference preparations and serum 
pools for release testing and stability 
studies  
US: Development and maintenance of 
US reference standards and serum pools 
to be used by licensed manufacturers for 
release testing and stability studies 
 
• EU: AIT products are typically labelled in 
in-house potency units. In specific 
circumstances, labelling can also be in 
protein content. 
US: AIT products are labelled according 
to a standardized potency. Where no 
standardized potency assay is available 
by FDA, products are labelled in units of 
weight per volume or protein content 
(protein nitrogen units). 
 
• EU: Aqueous extracts for subcutaneous, 
oral and sublingual AIT and tablets for 
sublingual AIT are available; Allergoids 
and adsorbed products are available.  
US: Mostly aqueous extracts for 
subcutaneous AIT are being used; Some 
sublingual AIT tablet products are 
available; no allergoids or adsorbed 
products are available. 
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